Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A new real-world study finds that taste aversion is just as likely to make children drop out of oral immunotherapy (OIT) for food allergies as adverse reactions. In a Swiss cohort of 307 children, 15% of OIT courses were discontinued, with taste aversion and adverse events each accounting for roughly 40% of dropouts. Milk had the highest discontinuation rate at 25%, while sesame and cashew had the lowest.
A new real-world study out of Switzerland reveals a surprising culprit behind oral immunotherapy (OIT) dropout in children: taste aversion. Researchers tracked 307 kids undergoing 406 OIT courses for IgE-mediated food allergies across 14 allergens — and found that 15% of treatment courses were discontinued. While adverse reactions are often assumed to be the main reason kids quit, taste aversion was nearly just as common a cause.
Among the 61 discontinued treatment courses, adverse events (41%) and taste aversion (39%) were neck-and-neck as the leading reasons for stopping. Notably, taste aversion tended to emerge later — typically after kids reached the maintenance phase — while adverse events prompted earlier dropouts (median 2.1 months vs. 5 months for taste aversion).
By the Numbers:
Why it matters: OIT is one of the few active treatment options for food allergies in children, making dropout a serious clinical concern. This study highlights that sensory and psychological barriers — not just medical ones — need to be addressed from the start of treatment to keep kids on track.
